Chinese Academy of

DMR-98-096 is a glycine transporter-1 (GlyT-1) inhibitor small-molecule therapeutic developed by Xiyuan Hospital of China Academy of Chinese Medical Sciences for the treatment of schizophrenia. The program is currently in Phase 2 development, with the most recent milestone dated 29 October 2013. GlyT-1 inhibition represents a distinct mechanistic approach to schizophrenia management, targeting the reuptake of glycine, a co-agonist at N-methyl-D-aspartate (NMDA) receptors. The sponsor has disclosed clinical trial activity in China under regulatory oversight, with multiple trial registrations visible on ClinicalTrials.gov spanning recent years (NCT04471480, NCT05916248, NCT07159906, NCT07174375, NCT07327411). The program's development trajectory and current regulatory status in China remain incompletely disclosed; specific efficacy data, safety profiles, and advancement milestones beyond October 2013 have not been publicly reported. The competitive landscape for schizophrenia includes numerous approved antipsychotics and adjunctive therapies, though GlyT-1 inhibition occupies a distinct pharmacological niche within that market. No partnership arrangements, licensing agreements, or peak sales projections have been disclosed for this program.

Schizophrenia remains a significant unmet medical need despite the availability of multiple antipsychotic agents. Existing therapies, including first-generation and atypical antipsychotics, are associated with substantial side-effect burdens—including metabolic syndrome, extrapyramidal symptoms, and weight gain—that limit patient adherence and long-term outcomes. GlyT-1 inhibition represents a mechanistically distinct approach that may offer improved tolerability or efficacy by enhancing NMDA receptor signaling through increased synaptic glycine availability, potentially addressing negative symptoms and cognitive impairment that remain inadequately treated by conventional dopamine antagonists.

The global schizophrenia therapeutics market encompasses both established antipsychotics and emerging mechanism-of-action compounds. Development of novel agents with improved side-effect profiles or efficacy against treatment-resistant symptoms remains commercially and clinically significant. DMR-98-096's development in China reflects the growing pharmaceutical innovation pipeline in Asia and the substantial patient population with schizophrenia in the region. Competitive positioning against approved agents such as aripiprazole, paliperidone, and clozapine will depend on demonstrated efficacy, safety, and tolerability advantages in Phase 2 and subsequent trials. The program's advancement status and likelihood of progression to Phase 3 remain undisclosed.

Drug Class: Glycine transporter-1 (GlyT-1) inhibitor

Modality: Small-molecule

Mechanism of Action: Not yet disclosed in available sources; presumed to inhibit glycine reuptake, thereby increasing synaptic glycine concentration and enhancing NMDA receptor co-agonism.

Target: Not yet disclosed; presumed to be SLC6A9 (glycine transporter-1).

Route of Administration: Not yet disclosed.

Molecular Type: Small-molecule chemical entity.

Related Therapies: GlyT-1 inhibition is a distinct mechanism within schizophrenia treatment; related approaches include NMDA receptor modulators and glycine-site agonists. Conventional comparators include dopamine antagonists (aripiprazole, paliperidone, clozapine) and other adjunctive agents.

First Approval: Not applicable; program remains in clinical development.

Patent Status: Not yet disclosed.

China (NMPA): DMR-98-096 is in clinical trials in China under NMPA oversight. Multiple trial registrations (NCT04471480, NCT05916248, NCT07159906, NCT07174375, NCT07327411) indicate ongoing Phase 2 development; specific regulatory milestones, trial approvals, and advancement decisions are not yet disclosed.

FDA (United States): Regulatory status in the United States is not yet disclosed.

EMA (European Union): Regulatory status in the European Union is not yet disclosed.

PMDA (Japan): Regulatory status in Japan is not yet disclosed.

Summary: The program's development is currently visible in China through clinical trial registrations. No approvals, regulatory designations (breakthrough therapy, orphan drug, etc.), or advancement to regulatory submission have been disclosed for any jurisdiction.

Development Status: DMR-98-096 remains in Phase 2 development with the most recent disclosed milestone from October 2013. The presence of multiple active trial registrations in China (spanning 2020–2024) suggests continued development activity; however, the absence of published results, regulatory updates, or advancement announcements since 2013 raises questions regarding program momentum and likelihood of Phase 3 progression.

Mechanistic Differentiation: GlyT-1 inhibition represents a distinct approach to schizophrenia treatment, targeting NMDA receptor co-agonism rather than dopamine antagonism. This mechanism may address treatment gaps in negative symptoms and cognitive dysfunction; however, clinical validation through Phase 2 efficacy and safety data remains undisclosed.

Competitive Implications: The schizophrenia market is mature and crowded with approved agents. Successful differentiation will require demonstrated superiority in efficacy, tolerability, or patient outcomes relative to established comparators. The program's lack of disclosed partnership, licensing, or commercial strategy limits visibility into sponsor commitment and commercialization plans.

Future Catalysts: Key milestones include Phase 2 trial completion and results disclosure, regulatory feedback from NMPA, potential Phase 3 initiation, and any partnership or licensing announcements. Publication of Phase 2 efficacy and safety data in peer-reviewed literature would provide critical evidence for competitive positioning.

Regulatory Pathway: Development appears focused on China; expansion to other jurisdictions (FDA, EMA) is not yet disclosed. The program's regulatory strategy and intended markets remain unclear.